Immunocore Holdings (IMCR) is back in focus after its latest earnings report, which showed year over year revenue growth and a smaller full year net loss, prompting investors to reassess the stock.
See our latest analysis for Immunocore Holdings.
The latest earnings report and upcoming conference schedule have not reversed recent share price pressure. The 90 day share price return of 17.66% and the 3 year total shareholder return of 39.74% point to fading momentum, despite a 1 year total shareholder return of 3.64%.
If this earnings update has you thinking about where else growth stories could emerge in healthcare, it might be worth checking out 32 healthcare AI stocks as a starting list of potential ideas.
With shares under pressure despite revenue of US$400.02 million and a narrower full year loss of US$35.51 million, the key question now is simple: is Immunocore undervalued or is the market already pricing in future growth?
Most Popular Narrative: 52% Undervalued
Immunocore's most followed narrative pegs fair value at $66.57 per share versus the last close at $31.93, presenting a wide valuation gap for investors to assess.
Momentum in pipeline diversification, progressing late stage trials in cutaneous melanoma (TEBE-AM, PRISM-MEL) and expanding into infectious and autoimmune diseases, reduces single product risk and sets the stage for multiple future revenue streams and earnings expansion. Robust commercial uptake of KIMMTRAK, demonstrated by 32% YoY revenue growth, 13 month duration of therapy, and deeper community penetration, indicates durable market share and the potential for continued operating leverage as scale increases.
Curious what earnings ramp, margin shift, and cash flow profile are reflected in that fair value? The narrative leans on aggressive growth, richer margins, and a premium multiple. The exact mix might surprise you.
Result: Fair Value of $66.57 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story still leans heavily on KIMMTRAK continuing to deliver, while costly late stage trials and any clinical setbacks could quickly change the earnings and valuation picture.
Find out about the key risks to this Immunocore Holdings narrative.
Next Steps
If the mix of optimism and caution in this story feels familiar, it could be worth checking the numbers yourself and acting before sentiment shifts. To see exactly what potential upsides others are focusing on, take a look at 4 key rewards.
Ready to uncover more investment ideas?
Do not stop your research with a single stock, use the Simply Wall Street Screener to line up a broader watchlist and avoid missing other potential opportunities.
- Spot potential value opportunities early by scanning our list of 47 high quality undervalued stocks that pair fundamentals with pricing that may warrant a closer look.
- Prioritise resilience first and sift through 73 resilient stocks with low risk scores that score well on lower risk factors before you put more capital to work.
- Explore ideas off the beaten path with a screener containing 24 high quality undiscovered gems that could otherwise sit under the radar of most investors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com